Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift
Independent validation confirms Algorae’s upgraded AI platform predicts drug synergies more accurately
Algorae Pharmaceuticals (ASX: 1AI) has recently reported positive preclinical results from an independent validation of its AlgoraeOS v2 (AOS2) drug-combination prediction platform, marking a technical de-risking milestone for the company’s core AI discovery engine.
The headline finding: AOS2 identified approximately a 2.5-fold higher proportion of confirmed synergistic combinations relative to predictions when compared with the earlier AOS1 model.
The validation was performed by the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre, under the supervision of Professor Kaylene Simpson and Chief Scientific Officer Dr James McKenna.
For investors, the significance is straightforward. This is the second validation study supporting the AlgoraeOS platform, and consistent results across independent programs strengthen confidence in the company’s discovery engine.
When big ASX news breaks, our subscribers know first
Inside the validation program
AlgoraeOS v2 was used to select 24 drugs predicted to show synergy when combined with CBD. These combinations were then assessed using in vitro (laboratory-based) assays across four established cancer cell lines.
The second Peter Mac collaboration established the specific parameters for this validation, narrowing an initial candidate pool of 90 down to 24 high-priority drug combinations before screening began across the four selected cancer cell lines.
Key study parameters included:
-
24 drugs predicted by AOS2, each tested in combination with CBD
-
Assessment across four cancer cell lines (T98G, A2058, K-562, RD)
-
96 assessments of CBD–drug–cell line combinations
-
Approximately 10,000 data points generated, including replicates and controls
-
Each combination analysed across four synergy models: Highest Single Agent (HSA), Bliss independence, Zero Interaction Potency (ZIP) and Loewe additivity
The broader prediction set was considerably larger. AOS2’s predictions spanned CBD in combination with more than 3,000 approved and investigational drugs, evaluated across 170 cell lines.
| Metric | AOS1 (prior) | AOS2 (current) | Significance |
|---|---|---|---|
| Confirmed synergies relative to predictions | Baseline (preliminary model) | ~2.5-fold higher proportion | Improved predictive accuracy |
| Uncertainty metrics | Not present | Added for each model prediction | Additional layer to triage candidates and assess model accuracy |
| Synergy model alignment | Three of four aligned | Three of four aligned | Supports consistency and repeatability |
Key findings and what improved
The AOS2 validation program delivered four key observations:
-
Improved predictive power — AOS2 identified approximately a 2.5-fold higher proportion of confirmed synergies relative to predictions compared with the preliminary AOS1 model, using previously defined internal thresholds.
-
Uncertainty metrics — a new AOS2 feature adding uncertainty metrics for each model prediction, providing an additional layer to improve predictive capacity and assess model accuracy.
-
Synergy model consistency — three of the four synergy models were closely aligned, supporting the consistency, robustness and repeatability of the synergy predictions.
-
Real-world synergy links — several potential synergistic combinations were identified across both validation programs, now candidates for further preclinical assessment alongside an intellectual property review.
Consistency across two independent studies strengthens confidence that the platform prioritises combinations more likely to show true biological synergy.
Chief Scientific Officer Dr James McKenna
“This validation program marks another important milestone in the testing and refinement of the AlgoraeOS platform. Conducted in collaboration with the VCFG, the program has enabled us to compare the enhanced AOS2 model against the preliminary version, providing valuable insight into the strength of the updated model, while identifying additional promising drug combinations for further assessment. We look forward to continuing the development of AlgoraeOS using a broader range of approved and investigational anchor drugs.”
What is AI-driven drug-combination discovery?
The AlgoraeOS platform applies machine learning and deep neural networks to screen vast numbers of drug pairings in silico (by computer) before any costly laboratory testing begins. The goal is to predict which combinations are likely to work well together.
The concept being tested is synergy. Independent validation is the step that confirms whether those predictions hold up under laboratory conditions.
Next steps: multi-anchor pipeline and grant-backed expansion
With this validation program complete, Algorae will consider further investigation into the most promising combinations and pursue intellectual property rights where applicable.
Building on the AOS2 results, the company is initiating validation of its multi-anchor program, first announced on 18 May 2026. The expanded pipeline is considerably larger in scale:
The multi-anchor pipeline expansion announced in May 2026 generated over 9 million in silico drug-drug-cell line predictions, with more than 6,000 combinations demonstrating synergy across multiple cell lines before any laboratory screening begins.
-
Extended to an additional 18 anchor drugs
-
Over 9 million potential drug–drug–cell line combinations evaluated
-
Over 6,000 combinations flagged as indicating potential synergy
-
A small subset to enter a further in vitro validation program with the VCFG
The multi-anchor program is co-funded by a $49,109 voucher awarded under the Phenomics Australia – Therapeutic Innovation Australia Pipeline Accelerator 2025-26 Round 2 scheme. The scheme attracted 28 applications, of which 13 were selected for funding.
This non-dilutive support reduces the total cost to the company of accessing the required experimental services in partnership with the VCFG.
The next major ASX story will hit our subscribers first
Why this matters for the investment case
Two independent validations now support the AlgoraeOS platform’s improving predictive accuracy, providing a de-risking signal for the company’s core discovery engine.
A growing pipeline of AI-identified synergistic combinations creates multiple future optionality points, including further preclinical work and potential intellectual property protection.
These developments sit within Algorae’s dual-focus model. Alongside the AlgoraeOS discovery engine, the company operates AlgoraeRx, a commercialisation business that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.
Taken together, the validation results and the expanding pipeline reinforce the technical credibility of the platform, while ongoing preclinical work and intellectual property review will determine which combinations advance.
Is the AlgoraeOS Platform Set to Redefine AI-Driven Drug Discovery?
Algorae Pharmaceuticals (ASX: 1AI) has received independent confirmation that its upgraded AlgoraeOS v2 platform identifies synergistic drug combinations at approximately 2.5 times the rate of its predecessor, with the validation conducted by the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre. Combined with a newly expanded multi-anchor pipeline spanning over 9 million in silico predictions, the company’s AI discovery engine is building a credible body of evidence across two independent studies.
Investors seeking a deeper understanding of the platform’s commercial potential and preclinical pipeline can explore the full Algorae Pharmaceuticals investor overview to assess the opportunity in detail. With non-dilutive grant funding secured and intellectual property reviews underway, the next phase of development is already under way.